Fludarabine in chronic leukaemia (original) (raw)

Fludarabine represents a significant advancement in the treatment of chronic lymphocytic leukaemia (CLL), especially when compared to traditional therapies like chlorambucil. This study presents the first comprehensive analysis comparing fludarabine's effectiveness and safety with CAP (cyclophosphamide, doxorubicin, and prednisone) in patients with advanced CLL. Results indicate that while fludarabine improves response rates and has a better toxicity profile, it does not necessarily extend overall survival in salvage patients, marking a complex picture for its role in CLL therapy.